Spin-outs
Stacks Image 655
MuOx Ltd was established in 2012 to translate our basic research findings towards developing an orally bioavailable small molecule Best-in-Class utrophin modulator for the treatment of Duchenne Muscular Dystrophy, a severe muscle-wasting disease. MuOx was acquired by Summit Therapeutics plc in 2013. Our research is currently focused on identifying and developing the next generation utrophin modulators.
Stacks Image 657
OxStem Immuno, launched in October 2018, aims to develop small molecules capable of modulating immune cell function with the intention of treating chronic wounds.
Stacks Image 649
OxStem Ocular, launched in August 2016, aims to identify a new class of drugs that will stimulate appropriate precursor cells within the retina of patients with a range of retinopathies, including Age-related Macular Degeneration (AMD), to stimulate retinal repair to restore vision.
Stacks Image 653
OxStem Beta, launched in October 2018, aims to develop therapeutics which will stimulate regeneration of insulin-producing beta cells, using small molecules, to treat types I and II diabetes.
Stacks Image 651
OxStem Ltd was launched in May 2016 to translate our basic research, in collaboration with our partners at Oxford, to identify new classes of drugs that can re-programme or stimulate existing endogenous cells – awakening previously defunct or dormant cellular processes. The company raised £16.9M in its seeding round, a record for a UK Bioscience spin-out company, to develop small molecule drug candidates to treat age-related conditions including cancer, neurodegenerative diseases and heart failure. Funding has enabled OxStem to fund the development of a series of daughter companies - each with a focus on a different large unmet therapeutic need.
Stacks Image 645
OxStem Cardio, launched in November 2016, aims to identify a new class of drugs that will stimulate resident cardiac precursor cells to increase cardiac muscle regeneration and improve functional recovery following myocardial infarction (MI).
Stacks Image 643
OxStem Neuro, launched in August 2016, aims to identify a new class of drugs that will stimulate de novo neuron production from neural stem cells that will compensate for disease pathology in neurodegenerative diseases, and restore cognitive function.
Stacks Image 647
OxStem Oncology, launched in May 2016, aims to identify new classes of drugs that will differentiate 'cancer stem-like cells' (CSLCs) to more benign states that will improve clinical outcomes and overcome resistance/relapse. Our current research is focusing on Acute Myeloid Leukaemia and Myelodysplastic Syndromes.